Monthly Roundup

Gene therapy for hemophilia shows variable efficacy, with some patients maintaining clotting factor expression for several years while others experience earlier declines. Pre-existing neutralizing antibodies, factor inhibitors, liver health, coexisting conditions, and age influence outcomes, as younger patients may lose transgene expression due to cell turnover. Monitoring involves assessing bleeding rates, clotting factor activity, and inhibitor development using one-stage assays, which are widely used but variable, and chromogenic assays, which are more consistent. Discrepancies between these assays, especially with the Factor IX Padua variant in hemophilia B, highlight the need for further study. Consolidating global data will improve understanding of long-term safety, efficacy, care standardization, and liver health challenges.